Postoperative PainNCT06982209
ANI-Guided Anesthetic Desflurane Consumption
A study testing Analgesia/Nociception Index (ANI) in people with Postoperative Pain and General Anesthesia, run by Wonkwang University Hospital at 1 site in South Korea.
Trial summary
General anesthesia requires precise titration of inhaled anesthetics like desflurane and opioids like remifentanil to balance sedation, analgesia, and hemodynamic stability. The Analgesia/Nociception Index (ANI), derived from heart rate variability (HRV), quantifies parasympathetic tone to assess… Read more about this study
- Who is it for?
- Ages 19 to 65 years
- Conditions the study is for
- Postoperative Pain, General Anesthesia, Laparoscopic Cholecystectomy
- What is being tested?
- Analgesia/Nociception Index (ANI)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 125 participants
- Where
- 1 siteSouth Korea
- Study dates
- 2 Jul 2026to 12 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- aged 19-65 years, American Society of Anesthesiologists (ASA) physical status I-II, scheduled for elective laparoscopic cholecystectomy under general anesthesia.
Who cannot join
- chronic pain, preoperative opioid use, cardiac arrhythmias, autonomic dysfunction, or contraindications to desflurane or remifentanil.
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Wonkwang University School of Medicine Hospital
Iksan, Jeollabuk-do, 54538
About this study
Official title: Analgesia/Nociception Index (ANI)-Guided Desflurane Titration Reduces Anesthetic Consumption in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial
General anesthesia requires precise titration of inhaled anesthetics like desflurane and opioids like remifentanil to balance sedation, analgesia, and hemodynamic stability. The Analgesia/Nociception Index (ANI), derived from heart rate variability (HRV), quantifies parasympathetic tone to assess nociception-antinociception balance on a 0-100 scale, with lower values indicating nociceptive stress. ANI analyzes high-frequency HRV components, reflecting parasympathetic inhibition during painful stimuli, making it a reliable indicator of intraoperative nociception. Studies validate the utility of ANI in detecting nociceptive events during laparoscopic surgery. ANI-guided opioid titration reduces opioid consumption and stabilizes hemodynamics, enhancing perioperative outcomes.
Read the detailed description
Study Design This prospective, single-center, randomized controlled trial receives approval from the [Institutional Review Board Name] (Approval No. 2024-01-05-21-004). Written informed consent is obtained from all participants.
Participants Eligible patients are aged 19-65 years, American Society of Anesthesiologists (ASA) physical status I-II, and are scheduled for elective laparoscopic cholecystectomy under general anesthesia. Exclusion criteria include chronic pain, preoperative opioid use, cardiac arrhythmias, autonomic dysfunction, or contraindications to desflurane or remifentanil.
Randomization and Blinding Patients are randomized (1:1) to Analgesia/Nociception Index (ANI)-guided or standard care groups using a computer-generated sequence in blocks of four. Group allocation is concealed in opaque, sealed envelopes, which are opened before induction. Anesthesiologists remain unblinded due to ANI monitoring requirements, but patients and postoperative outcome assessors remain blinded to reduce bias.
Anesthesia Protocol Anesthesia is induced with propofol (2 mg/kg) and rocuronium (0.6 mg/kg). Maintenance includes desflurane and remifentanil (0.1 µg/kg/min continuous infusion). Ventilation maintains normocapnia (end-tidal Carbon dioxide: 35-40 mmHg). Bispectral index (BIS) is monitored to ensure hypnotic depth (target: 40-60).
Novel Metrics
In addition to standard intraoperative management, the following novel physiological and recovery-related metrics are assessed to enhance the evaluation of ANI-guided anesthesia:
- ∆ANI (Dynamic Change of ANI): The percentage change in ANI at specific surgical stimuli (e.g., skin incision, trocar insertion) is recorded as: ∆ANI = (ANI_post - ANI_pre) / ANI_pre × 100.
- Autonomic Nervous System Indicators:
- Heart Rate Variability (HRV): High Frequency (HF) and Low Frequency (LF)/HF ratio are calculated at baseline, mid-surgery, and end-surgery. Continuous beat-to-beat blood pressure (BP) and lead II electrocardiogram (ECG) are recorded noninvasively for 5 minutes using the equipment. HRV parameters are extracted using Software.
- Baroreflex Sensitivity (BRS): BRS is assessed pre-induction and intraoperatively. It is quantified using the spontaneous sequence method with regression analysis between Blood Pressure and respiratory rate intervals, measured with the equipment and analyzed with HRV Software.
Recovery Room Metrics
- Post-Anesthesia Care Unit (PACU) Length of Stay (LOS): Time from PACU entry to discharge readiness is recorded.
- Additional Analgesic Requirement: Any supplemental pain medication and dosage are recorded during PACU stay.
- Postoperative Nausea and Vomiting (PONV): Incidence is recorded within the first two postoperative hours.
Patient-Reported Outcomes
- Satisfaction Scores (Visual analogue scale [VAS]0-10): Are assessed at PACU discharge and on postoperative day 1 (POD1).
- ANI Group: Desflurane starts at 1 Minimum Alveolar Concentration (MAC) (~6 Vol%) and is titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI <50 prompts an increase; ANI >70 prompts a decrease.
- Control Group: Desflurane is titrated based on vital signs and BIS 40-60 per institutional protocol.
ANI is monitored using the ANI monitor in both groups, but only guides adjustments in the ANI group. Hemodynamic data are recorded every 5 minutes.
Emergence and Recovery At the end of the surgery, desflurane and remifentanil are discontinued. Neuromuscular blockade is monitored using Train-of-Four (TOF) stimulation. When TOF count reaches ≥2, sugammadex (2 mg/kg) is administered to reverse rocuronium. Extubation occurs when TOF ratio >0.9, with adequate spontaneous breathing and responsiveness to verbal commands. Emergence time is recorded as time from anesthetic cessation to eye opening.
Outcome Measures
- Primary Outcome: Mean end-tidal desflurane concentration (Vol%).
- Secondary Outcomes:
- Emergence time (min).
- Postoperative pain (VAS, 0-10) at 30 min post-extubation.
- Intraoperative hemodynamic stability (hypertension [Mean arterial pressure > 100 mmHg] or tachycardia [HR >100 bpm]).
- ∆ANI at surgical stimuli.
- HRV metrics (HF, LF/HF ratio).
- Baroreflex Sensitivity (BRS).
- PACU LOS.
- Requirements and dosage of additional analgesics in PACU.
- Incidence of PONV within 2 hours post-op.
- Patient satisfaction (PACU discharge and postoperative day 1).
- Being tested
- Analgesia/Nociception Index (ANI)
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Analgesia/Nociception Index (ANI)Device
ANI was monitored using the ANI monitor (MetroDoloris, France) in both groups, but only guided adjustments in the ANI group
| Study group | Role | What they receive |
|---|---|---|
| ANI-guided group | Experimental | Desflurane started at 1 MAC (~6 Vol%), titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI <50 prompted an increase; ANI >70 prompted a decrease Receives: Device: Analgesia/Nociception Index (ANI) |
| Control group | Active comparator | Desflurane was titrated based on vital signs (heart rate, blood pressure) and BIS 40-60, per institutional protocol. Receives: Device: Analgesia/Nociception Index (ANI) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean End-Tidal Desflurane Concentration
The average end-tidal desflurane concentration (Vol%) during maintenance of general anesthesia, measured using continuous gas monitoring. Desflurane delivery is titrated based on ANI (Analgesia/Nociception Index) in the intervention group and based on vital signs in the control group.
Measured: From induction of anesthesia to end of surgery (approximately 60 minutes)
Secondary outcomes (5)
Emergence Time
Time from discontinuation of anesthetics to eye opening upon verbal command, recorded in minutes.
Measured: At the end of surgery until eye opening (approximately 5-15 minutes)
Post-Anesthesia Care Unit (PACU) Length of Stay
Time from PACU admission to discharge readiness, measured in minutes.
Measured: From PACU entry to PACU discharge criteria fulfillment (approximately 30-90 minutes)
Additional Analgesic Requirement in PACU
Number of patients requiring additional analgesics in PACU and total morphine-equivalent dose administered.
Measured: During PACU stay (up to 2 hours after surgery)
Incidence of Postoperative Nausea and Vomiting (PONV)
Presence of nausea or vomiting events recorded within the first two postoperative hours.
Measured: Within 2 hours after surgery
Patient Satisfaction
Patient-reported satisfaction using a Visual Analog Scale (0-10) at PACU discharge and on postoperative day 1.
Measured: At PACU discharge and 24 hours postoperatively (POD1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2025
- Study start2 Jul 2026
- Primary completion12 Jul 2026
- Study completion12 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- * ANI Group: Desflurane started at 1 MAC (\~6 Vol%), titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI \<50 prompted an increase; ANI \>70 prompted a decrease. * Control Group: Desflurane was titrated based on vital signs (heart rate, blood pressure) and BIS 40-60, per institutional protocol.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 125 participants (actual)
Sponsor and investigators
- Lead sponsor
- Wonkwang University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cheol Lee,MD,PhD,, Wonkwang University Hospital
- Investigators
- Cheol Lee, M.D.,Ph.D, Principal investigator, Wonkwang University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06982209
- Sponsor's protocol ID
- Wonkwang UH20
- Status last verified
- Aug 2026
- First submitted
- 13 May 2025
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analgesia/Nociception Index (ANI)-Guided Desflurane Titration Reduces Anesthetic Consumption in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06982209
- Acronym / sponsor ID
- Wonkwang UH20
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 125 participants (actual)
- Lead sponsor
- Wonkwang University HospitalUniversity, hospital or other
- Study start
- 2 Jul 2026 (actual)
- Primary completion
- 12 Jul 2026 (actual)
- Study completion
- 12 Aug 2026 (actual)
- First posted
- 21 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
General anesthesia requires precise titration of inhaled anesthetics like desflurane and opioids like remifentanil to balance sedation, analgesia, and hemodynamic stability. The Analgesia/Nociception Index (ANI), derived from heart rate variability (HRV), quantifies parasympathetic tone to assess nociception-antinociception balance on a 0-100 scale, with lower values indicating nociceptive stress. ANI analyzes high-frequency HRV components, reflecting parasympathetic inhibition during painful stimuli, making it a reliable indicator of intraoperative nociception. Studies validate the utility of ANI in detecting nociceptive events during laparoscopic surgery. ANI-guided opioid titration reduces opioid consumption and stabilizes hemodynamics, enhancing perioperative outcomes.
Detailed description
Study Design This prospective, single-center, randomized controlled trial receives approval from the [Institutional Review Board Name] (Approval No. 2024-01-05-21-004). Written informed consent is obtained from all participants.
Participants Eligible patients are aged 19-65 years, American Society of Anesthesiologists (ASA) physical status I-II, and are scheduled for elective laparoscopic cholecystectomy under general anesthesia. Exclusion criteria include chronic pain, preoperative opioid use, cardiac arrhythmias, autonomic dysfunction, or contraindications to desflurane or remifentanil.
Randomization and Blinding Patients are randomized (1:1) to Analgesia/Nociception Index (ANI)-guided or standard care groups using a computer-generated sequence in blocks of four. Group allocation is concealed in opaque, sealed envelopes, which are opened before induction. Anesthesiologists remain unblinded due to ANI monitoring requirements, but patients and postoperative outcome assessors remain blinded to reduce bias.
Anesthesia Protocol Anesthesia is induced with propofol (2 mg/kg) and rocuronium (0.6 mg/kg). Maintenance includes desflurane and remifentanil (0.1 µg/kg/min continuous infusion). Ventilation maintains normocapnia (end-tidal Carbon dioxide: 35-40 mmHg). Bispectral index (BIS) is monitored to ensure hypnotic depth (target: 40-60).
Novel Metrics
In addition to standard intraoperative management, the following novel physiological and recovery-related metrics are assessed to enhance the evaluation of ANI-guided anesthesia:
- ∆ANI (Dynamic Change of ANI): The percentage change in ANI at specific surgical stimuli (e.g., skin incision, trocar insertion) is recorded as: ∆ANI = (ANI_post - ANI_pre) / ANI_pre × 100.
- Autonomic Nervous System Indicators:
- Heart Rate Variability (HRV): High Frequency (HF) and Low Frequency (LF)/HF ratio are calculated at baseline, mid-surgery, and end-surgery. Continuous beat-to-beat blood pressure (BP) and lead II electrocardiogram (ECG) are recorded noninvasively for 5 minutes using the equipment. HRV parameters are extracted using Software.
- Baroreflex Sensitivity (BRS): BRS is assessed pre-induction and intraoperatively. It is quantified using the spontaneous sequence method with regression analysis between Blood Pressure and respiratory rate intervals, measured with the equipment and analyzed with HRV Software.
Recovery Room Metrics
- Post-Anesthesia Care Unit (PACU) Length of Stay (LOS): Time from PACU entry to discharge readiness is recorded.
- Additional Analgesic Requirement: Any supplemental pain medication and dosage are recorded during PACU stay.
- Postoperative Nausea and Vomiting (PONV): Incidence is recorded within the first two postoperative hours.
Patient-Reported Outcomes
- Satisfaction Scores (Visual analogue scale [VAS]0-10): Are assessed at PACU discharge and on postoperative day 1 (POD1).
- ANI Group: Desflurane starts at 1 Minimum Alveolar Concentration (MAC) (~6 Vol%) and is titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI <50 prompts an increase; ANI >70 prompts a decrease.
- Control Group: Desflurane is titrated based on vital signs and BIS 40-60 per institutional protocol.
ANI is monitored using the ANI monitor in both groups, but only guides adjustments in the ANI group. Hemodynamic data are recorded every 5 minutes.
Emergence and Recovery At the end of the surgery, desflurane and remifentanil are discontinued. Neuromuscular blockade is monitored using Train-of-Four (TOF) stimulation. When TOF count reaches ≥2, sugammadex (2 mg/kg) is administered to reverse rocuronium. Extubation occurs when TOF ratio >0.9, with adequate spontaneous breathing and responsiveness to verbal commands. Emergence time is recorded as time from anesthetic cessation to eye opening.
Outcome Measures
- Primary Outcome: Mean end-tidal desflurane concentration (Vol%).
- Secondary Outcomes:
- Emergence time (min).
- Postoperative pain (VAS, 0-10) at 30 min post-extubation.
- Intraoperative hemodynamic stability (hypertension [Mean arterial pressure > 100 mmHg] or tachycardia [HR >100 bpm]).
- ∆ANI at surgical stimuli.
- HRV metrics (HF, LF/HF ratio).
- Baroreflex Sensitivity (BRS).
- PACU LOS.
- Requirements and dosage of additional analgesics in PACU.
- Incidence of PONV within 2 hours post-op.
- Patient satisfaction (PACU discharge and postoperative day 1).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- * ANI Group: Desflurane started at 1 MAC (~6 Vol%), titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI <50 prompted an increase; ANI >70 prompted a decrease. * Control Group: Desflurane was titrated based on vital signs (heart rate, blood pressure) and BIS 40-60, per institutional protocol.
| Arm | Type | Receives |
|---|---|---|
| ANI-guided group | Experimental | Device: Analgesia/Nociception Index (ANI)Desflurane started at 1 MAC (~6 Vol%), titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI <50 prompted an increase; ANI >70 prompted a decrease |
| Control group | Active comparator | Device: Analgesia/Nociception Index (ANI)Desflurane was titrated based on vital signs (heart rate, blood pressure) and BIS 40-60, per institutional protocol. |
Who may qualify
- Ages
- 19 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- aged 19-65 years, American Society of Anesthesiologists (ASA) physical status I-II, scheduled for elective laparoscopic cholecystectomy under general anesthesia.
Key exclusion criteria (1 listed)
- chronic pain, preoperative opioid use, cardiac arrhythmias, autonomic dysfunction, or contraindications to desflurane or remifentanil.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Analgesia/Nociception Index (ANI)ANI was monitored using the ANI monitor (MetroDoloris, France) in both groups, but only guided adjustments in the ANI group | Device | ANI-guided group, Control group |
Primary outcome
Mean End-Tidal Desflurane Concentration
Time frame: From induction of anesthesia to end of surgery (approximately 60 minutes)
The average end-tidal desflurane concentration (Vol%) during maintenance of general anesthesia, measured using continuous gas monitoring. Desflurane delivery is titrated based on ANI (Analgesia/Nociception Index) in the intervention group and based on vital signs in the control group.
5 secondary outcomes
Emergence Time
Time frame: At the end of surgery until eye opening (approximately 5-15 minutes)
Post-Anesthesia Care Unit (PACU) Length of Stay
Time frame: From PACU entry to PACU discharge criteria fulfillment (approximately 30-90 minutes)
Additional Analgesic Requirement in PACU
Time frame: During PACU stay (up to 2 hours after surgery)
Incidence of Postoperative Nausea and Vomiting (PONV)
Time frame: Within 2 hours after surgery
Patient Satisfaction
Time frame: At PACU discharge and 24 hours postoperatively (POD1)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
RecruitingPhase 2/3
Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children
Pain, Postoperative
Not yet recruitingPhase 3
Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Active, not recruiting
Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty
Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cheol Lee, M.D.,Ph.D principal investigator
Wonkwang University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Analgesia/Nociception Index (ANI) in people with Postoperative Pain and General Anesthesia, run by Wonkwang University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean End-Tidal Desflurane Concentration (time frame: From induction of anesthesia to end of surgery (approximately 60 minutes)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.